Skip to Content

Rx Redefined skips 'intermediary’ 

Rx Redefined skips 'intermediary’ 

Brandon BootsOAKLAND, Calif. - Rx Redefined, a platform that allows physicians to manage the distribution of medical supplies for their patients, recently raised $8 million in Series A funding, a sign that founder and CEO Brandon Boots is on to something. 

Boots started Rx Redefined in 2018 because he believes, when it comes to obtaining medical supplies for a chronic condition, the prescription process is broken. 

"We have experienced tremendous growth in the last year,” said Boots. “With the increased funding, we plan to invest in continued sales acceleration and operational efficiencies, and expand key product features.” 

The funding round was led by Crosscut Ventures Management, with participation from Tusk Venture Partners, Silverton Partners, Pisgah Fund and Jeff Immelt, former CEO of General Electric. 

Boots’ goal for Rx Redefined is to reconnect the prescription process, ensuring that the product a patient trains on in the clinic is the same product they have access to when they go home. 

“After working more than a decade in the medical device and supply industry, I’ve seen it all—the bait-and-switch tactics, delivery delays, lack of concern for the patient’s needs, and the increasing burden for medical practices to close the gap—and I thought, ‘We can do better,’” said Boots. 

Rx Redefined allows physicians to directly order and fulfill supplies, reducing care gaps and improving overall experience. It also oversees licensing, billing and supply chain services for the physician group. 

“Too frequently, the patient gets lost amongst the paper forms, faxes, and handoffs and struggles to get their product in an efficient or timely manner,” said Boots. “Or worse, the supplier intentionally switches the patient to a lower cost product to increase their margins. By removing the intermediary, we can ensure the patient gets the right product without the delays, hoops or hassles.” 

Over the last year, Rx Redefined grew booked sales by 10x and increased its physician population by 450%, prompting investors to take notice.  

"We have experienced tremendous growth in the last year,” said Boots. “With the increased funding, we plan to invest in continued sales acceleration and operational efficiencies, and expand key product features.” 

Comments

To comment on this post, please log in to your account or set up an account now.